AOD-9604 research guide

AOD-9604 in Cravant — Fat Loss Peptide Research Guide

AOD-9604 research guide for Cravant. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.

Skip to Sourcing Guide Order AOD-9604 →

Cravant Guide to AOD-9604 Research

The search for AOD-9604 in Cravant almost always leads to the same conclusion: research peptides are sourced from specialist online vendors, not high-street stores. This matters because AOD-9604 quality ranges widely across the market — from verified research-grade material to mislabeled or underdosed compounds — and the vendor is the entire quality system. The core quality markers for AOD-9604 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-matched Certificate of Analysis. The sections below cover what Cravant researchers need to know about purchasing, testing, and working with AOD-9604 for research purposes.

The Science Behind AOD-9604

CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Cravant comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.

Where to Buy AOD-9604 — A Researcher's Guide

The most consistent path to quality AOD-9604 is starting with community forums — peptide forums aggregate real purchasing experience that are more reliable than search results. Mass spectrometry in the COA verifies that the main HPLC peak is actually AOD-9604 and not another compound with similar chromatographic behaviour — HPLC purity alone cannot verify molecular identity. Community reputation in research forums is a useful additional signal to COA verification — vendors with sustained positive community feedback have proved themselves through consistent results. Bacteriostatic water is the appropriate reconstitution medium for AOD-9604 — it contains 0.9% benzyl alcohol that inhibits bacterial growth and extends reconstituted shelf life to 30 days refrigerated.

Order AOD-9604 — ships to Cravant
COA-verified · International tracking · Research grade
Order Now →

AOD-9604 Safety, Handling & Research Protocols

All use of AOD-9604 in Cravant or anywhere constitutes research use — this compound is not approved for therapeutic human application, and all handling should adhere to research compound handling standards. Lyophilised AOD-9604 should be placed in the freezer at −20°C straight away; repeated freeze-thaw cycles of reconstituted material should be avoided by preparing small aliquots before storage. Verify the endotoxin level in your AOD-9604 batch COA before any protocol involving administration — look for results reported in endotoxin units per mg or mL and compare against acceptable research limits for your application. Protocol documentation — keeping clear records of compound, timing, and method — is a sound practice for any AOD-9604 protocol that allows any unexpected observations to be properly contextualised.

Frequently Asked Questions

What is AOD-9604?

AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.

What is the clinical trial history of AOD-9604?

AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.

How does AOD-9604 differ from growth hormone?

AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.

Order AOD-9604 today
COA-verified · International shipping available
Order Now →